We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Plasma ACE2 Predicts Prognosis of COVID-19 Hospitalized Patients

By LabMedica International staff writers
Posted on 24 Jun 2021
Print article
Image: A molecular model of the spike proteins (red) of SARS-CoV-2 binding to the angiotensin-converting enzyme 2 (ACE2) protein, the receptor (blue) which is it’s entry route to the target cell (Photo courtesy of the Juan Gaertner/ Science Photo Library)
Image: A molecular model of the spike proteins (red) of SARS-CoV-2 binding to the angiotensin-converting enzyme 2 (ACE2) protein, the receptor (blue) which is it’s entry route to the target cell (Photo courtesy of the Juan Gaertner/ Science Photo Library)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a devastating global pandemic. The disease caused by SARS-CoV-2 infection has been termed coronavirus disease of 2019 (COVID-19) with clinical manifestations ranging from asymptomatic and subclinical infection to severe hyperinflammatory syndrome and death.

SARS-CoV-2 binds to the angiotensin converting enzyme 2 (ACE2) receptor enabling entrance into cells through membrane fusion and endocytosis. The ACE2-receptor is distributed in different tissues including vascular endothelial cells, smooth muscle cells, nasal and oral mucosa, enterocytes within the intestines, and is especially abundant in the kidneys and type II alveolar pneumocytes in the lungs.

An international team of scientists collaborating with those at Aarhus University Hospital (Aarhus, Denmark) analyzed data from a large longitudinal study of 306 COVID-19-positive patients and 78 COVID-19-negative patients (Massachusetts General Hospital Emergency Department COVID-19 Cohort). Subjects included patients 18 years or older, who were in acute respiratory distress with a clinical concern for COVID-19 upon arrival to the Emergency Department. Samples from the patients were analyzed by the Olink Explore 1536 platform (Olink, Uppsala, Sweden), which includes measurement of the ACE2 protein. The Olink platform is based on Proximity Extension Assay (PEA) technology.

The team reported that the analysis demonstrated that high admission plasma ACE2 in patients with COVID-19 was associated with increased maximal illness severity within 28 days (odds ratio [OR] = 1.8). In models correcting for age, body mass index (BMI), hypertension, and pre-existing heart conditions, kidney disease, lung disease, diabetes, and immunosuppressive conditions, significant associations were still observed between plasma ACE2 at admission and maximal illness severity within 28 days.

Further, studies found that plasma ACE2 was also significantly higher in patients with COVID-19 with hypertension compared with patients without hypertension, and in patients with pre-existing heart conditions and kidney disease compared with those without these comorbidities. However, there was no significant difference in plasma ACE2 comparing patients with or without pre-existing lung disease, diabetes, or immunosuppressive conditions. Additionally, elevated plasma ACE2 in COVID-19-positive patients was significantly associated with increasing age, but there was no significant association between plasma ACE2 and BMI.

Tue W. Kragstrup, MD, an associate professor and lead author of the study, said, ““Elevated baseline plasma ACE2 in COVID-19 patients was significantly associated with increased disease severity during the 28-day study period. This indicates that abundant ACE2 production could be involved in increased viral spread and disease burden.”

The authors concluded that the design of the data analysis using the Olink platform does not allow assessment of quantitative differences. However, previous studies have described a positive correlation between plasma ACE2 and ACE1 activity. This is interesting because ACE1 (serum ACE) analysis is a standardized test in most hospital laboratories. Therefore, their study encourages quantitative investigations of both plasma ACE 1 and 2 in COVID-19. The study was published on June 4, 2021 in the journal PLOS ONE.

Related Links:
Aarhus University Hospital
Olink


New
Gold Supplier
POC Test Reader
NycoCard READER II
New
Fecal Occult Blood Test
iFOB Assay
New
Pipettor
Corning Step-R Repeating Pipettor
New
D-Dimer Test
Epithod 616 D-Dimer Kit

Print article
SUGENTECH INC.

Channels

Microbiology

view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more

Pathology

view channel
Image: Breast cancer spread uncovered by new molecular microscopy (Photo courtesy of Wellcome Sanger Institute)

New Molecular Microscopy Tool Uncovers Breast Cancer Spread

Breast cancer commonly starts when cells start to grow uncontrollably, often due to mutations in the cells. Overtime the tumor becomes a patchwork of cells, called cancer clones, each with different mutations.... Read more

Industry

view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.